Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026761769> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W3026761769 endingPage "S344" @default.
- W3026761769 startingPage "S344" @default.
- W3026761769 abstract "To identify the patient-reported health-related quality of life (HRQOL) of patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN). A systematic literature review (SLR) was conducted in PubMed, Embase, and Cochrane from January 1, 2009, to May 31, 2019, using search terms for impact on patient (all ages) HRQOL. The HRQOL SLR was part of a broader SLR to understand patient characteristics, treatment patterns, and health care resource use and costs associated with NF1 + PN. Seven studies were identified that described the HRQOL of children, adolescent, and adult patients with NF1 + PN, including development of a conceptual model (n=1), conduct of a HRQOL cross-sectional survey study (n= 2), conduct of a phase 2 longitudinal study measuring HRQOL (n=1), and measuring pain interference with HRQOL (n=3). The conceptual framework included five domains: pain, social functioning, physical function impact, stigma, and emotional distress. In a survey study, HRQOL was more altered for patients with NF1 + PN than patients with NF-1 without PN regarding symptoms and feelings, and during school or holidays. In another survey study, children with NF1 + PN reported worse HRQOL scores than population norms on most domains. Children with NF1 + PN reporting pain also had significantly worse symptoms and functioning on most HRQOL domains compared with population norms. Pain interferes with daily functioning in most youth with NF1 + PN even when using pain medication. In a phase 2 longitudinal study with selumetinib, 74% of patients had clinically significant decreases of > 2 points in their target tumor pain from baseline to cycle 12, and child physical domain scores improved significantly (p<0.05). NF1 + PN has a substantial impact on HRQOL including physical, social, and emotional function, and pain, highlighting the need for effective drug therapies." @default.
- W3026761769 created "2020-05-29" @default.
- W3026761769 creator A5007009548 @default.
- W3026761769 creator A5013552023 @default.
- W3026761769 creator A5016712597 @default.
- W3026761769 creator A5072341536 @default.
- W3026761769 creator A5079850171 @default.
- W3026761769 creator A5081663611 @default.
- W3026761769 date "2020-05-01" @default.
- W3026761769 modified "2023-09-27" @default.
- W3026761769 title "PRO85 IMPACT OF NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS ON PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE" @default.
- W3026761769 doi "https://doi.org/10.1016/j.jval.2020.04.1306" @default.
- W3026761769 hasPublicationYear "2020" @default.
- W3026761769 type Work @default.
- W3026761769 sameAs 3026761769 @default.
- W3026761769 citedByCount "0" @default.
- W3026761769 crossrefType "journal-article" @default.
- W3026761769 hasAuthorship W3026761769A5007009548 @default.
- W3026761769 hasAuthorship W3026761769A5013552023 @default.
- W3026761769 hasAuthorship W3026761769A5016712597 @default.
- W3026761769 hasAuthorship W3026761769A5072341536 @default.
- W3026761769 hasAuthorship W3026761769A5079850171 @default.
- W3026761769 hasAuthorship W3026761769A5081663611 @default.
- W3026761769 hasBestOaLocation W30267617691 @default.
- W3026761769 hasConcept C126322002 @default.
- W3026761769 hasConcept C142724271 @default.
- W3026761769 hasConcept C159110408 @default.
- W3026761769 hasConcept C1862650 @default.
- W3026761769 hasConcept C2778984943 @default.
- W3026761769 hasConcept C2779134260 @default.
- W3026761769 hasConcept C2779951463 @default.
- W3026761769 hasConcept C2908647359 @default.
- W3026761769 hasConcept C3019006561 @default.
- W3026761769 hasConcept C70410870 @default.
- W3026761769 hasConcept C71924100 @default.
- W3026761769 hasConcept C99454951 @default.
- W3026761769 hasConceptScore W3026761769C126322002 @default.
- W3026761769 hasConceptScore W3026761769C142724271 @default.
- W3026761769 hasConceptScore W3026761769C159110408 @default.
- W3026761769 hasConceptScore W3026761769C1862650 @default.
- W3026761769 hasConceptScore W3026761769C2778984943 @default.
- W3026761769 hasConceptScore W3026761769C2779134260 @default.
- W3026761769 hasConceptScore W3026761769C2779951463 @default.
- W3026761769 hasConceptScore W3026761769C2908647359 @default.
- W3026761769 hasConceptScore W3026761769C3019006561 @default.
- W3026761769 hasConceptScore W3026761769C70410870 @default.
- W3026761769 hasConceptScore W3026761769C71924100 @default.
- W3026761769 hasConceptScore W3026761769C99454951 @default.
- W3026761769 hasLocation W30267617691 @default.
- W3026761769 hasOpenAccess W3026761769 @default.
- W3026761769 hasPrimaryLocation W30267617691 @default.
- W3026761769 hasRelatedWork W1509473538 @default.
- W3026761769 hasRelatedWork W1834687338 @default.
- W3026761769 hasRelatedWork W1982096523 @default.
- W3026761769 hasRelatedWork W2006810578 @default.
- W3026761769 hasRelatedWork W2038307047 @default.
- W3026761769 hasRelatedWork W2114669392 @default.
- W3026761769 hasRelatedWork W2164060246 @default.
- W3026761769 hasRelatedWork W2973108776 @default.
- W3026761769 hasRelatedWork W4248202869 @default.
- W3026761769 hasRelatedWork W2122388284 @default.
- W3026761769 hasVolume "23" @default.
- W3026761769 isParatext "false" @default.
- W3026761769 isRetracted "false" @default.
- W3026761769 magId "3026761769" @default.
- W3026761769 workType "article" @default.